Crossmark

Combination of arsenic trioxide and apatinib synergistically inhibits small cell lung cancer by down-regulating VEGFR2/mTOR and Akt/c-Myc signaling pathway via GRB10

Crossref DOI link: https://doi.org/10.1186/s41065-024-00330-2

Published Online: 2024-09-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Yao

Shang, Yu

Shi, Si

He, Yaowu

Shi, Wenchao

Wang, Menghan

Wang, Qi

Xu, Dandan

Shi, Ce

Chen, Hong
Funding

Funding for this research was provided by:

Wu Jieping Medical Foundation (320.6750.2021-16-24)
License Information

Text and Data Mining valid from 2024-09-02

Version of Record valid from 2024-09-02
More Information

Article History

Received: 7 June 2024

Accepted: 10 August 2024

First Online: 2 September 2024

Declarations

:

: This animal study was reviewed and approved by the Experimental Animal Center of the Second Affiliated Hospital of Harbin Medical University. The studies involving human participants were reviewed and approved by the Medical Ethics Committee of The Second Affiliated Hospital of Harbin Medical University.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below